34
Participants
Start Date
February 28, 2006
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
Cyclophosphamide
Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Fludarabine
Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Rituximab
Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Buenos Aires
Caracas
Córdoba
Buenos Aires
Buenos Aires
Buenos Aires
La Plata
Pilar
Rosario
Hoffmann-La Roche
INDUSTRY